MedTrace Logo

Safety and Pharmacokinetic of Donepezil Pamoate in Healthy Subjects

NCT03932916 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2020-09-29

No results posted yet for this study

Summary

The objective of this study is to evaluate the safety and pharmacokinetic profiles of HHT201 in healthy subjects.

Conditions

Interventions

DRUG

Donepezil Pamoate for Injection 17mg

A dosage of 17mg HHT201 will be injected into the muscle in the gluteus once.

DRUG

Donepezil Pamoate for Injection 34mg

A dosage of 34mg HHT201 will be injected into the muscle in the gluteus once.

DRUG

Donepezil Hydrochloride 5mg

A tablet of 5mg Donepezil Hydrochloride will be administered once.

Sponsors & Collaborators

  • Shanghai Synergy Pharmaceutical Sciences Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Huafang Li, PhD · Shanghai Mental Health Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-02
Primary Completion
2020-08-06
Completion
2020-09-11

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03932916 on ClinicalTrials.gov